header logo image

Reaction to IOM: California Stem Cell Directors Approve Plan on Conflicts of Interest and More

♫
♫
January 27th, 2013 8:06 am

Directors of the $3 billion California
stem cell agency today approved a far-reaching plan aimed at resolving long-standing
conflict of interest issues involving the agency's governing board
and also at helping to maintain credibility with the public.

Jonathan Thomas
CIRM photo
The framework of the proposal by CIRM
Chairman J.T. Thomas moved forward on a 23-0 vote with one
abstention. He laid out the plan in response to sweeping recommendations from a blue-ribbon study by the Institute of Medicine. Details will be worked out and come back to the board in March. 
Acknowledging that many board members
were not pleased with the IOM criticism of the agency, Thomas said, 

“This is one of those times that we must move forward and compromise.” 

He
said issues such conflicts of interest have “stolen focus” from
the good scientific work that the agency has funded.
Thomas was reacting to the $700,000 IOM
study commissioned by CIRM governing board. The IOM recommendations
called for removing conflict
of interest problems, cleaning up a troubling dual-executive arrangement
and fundamentally changing the nature of the governing board. The IOM proposals would strip the board of its ability to approve individual grants,
greatly strengthen the role of the agency's president, significantly
alter the role of patient advocates on the governing board and engage
the biotech industry more vigorously.
Thomas' plan, which would be put in
place for up to a one-year trial period, would not do all that the
IOM wanted, but would move strongly in that direction.
State Controller John Chiang, chairman
of the only state entity with financial oversight over CIRM, endorsed
most of the proposal, said deputy controller Ruth Holton-Hodson. She
told CIRM directors that Thomas' plan was thoughtful and positive,
although Chiang did not support continued involvement of the chairman
in day-to-day operations.
The Thomas plan, which would not require legislative approval, would:
  • Have 13 members of the 29-member board
    refrain from voting on specific grant applications. The 13 would be from institutions that could benefit from CIRM grants. They would be
    allowed to participate in discussions. Thomas said this would deal
    with financial conflict of interest questions. 
  • Increase industry participation of
    industry in grant application review and step up business involvement
    internally at CIRM, including development of RFAs.
  • Redirect all scientific appeals to
    staff to evaluate for possible re-review before they go to the full
    board.
  • Move “programmatic” review of
    grants to public sessions of the full board instead of being held
    behind closed doors during grant review sessions. Patient advocate
    directors now sitting on the grant review group would no longer be
    allowed to vote during the closed-door review sessions, but they
    could participate in the discussion.

It appears, however, that the Thomas
plan would do little to deal with the dual-executive problems identified
by the IOM.

Consumer Watchdog's John M. Simpson, a
long observer of the stem cell agency, welcomed the response by
CIRM. Writing on his blog, Simpson said,

 "It looks like
the message is finally getting through to California's stem cell
agency board....
Part of what is driving the new
approach is the realization that CIRM will need to find a new source
of funding -- possibly going back to the voters -- if it is to
continue.  As Thomas told the board today, 'If we don't
have credibility, we won't have a chance of sustaining the agency.'"

During the lengthy debate this
afternoon, one director after another said they did not agree with
all that the IOM had to say, but said maintaining credibility and
trust was the key to the sustainability of the organization.
CIRM will run out of money for new
grants in less than four years. Thomas said he is working on a plan
to continue the agency's effort into the future. Details of that will
be disclosed later, he said.

(Editor's note: An earlier version of this item, based on incorrect information from CIRM, said the vote was 21-0. The correct figure is 23-0.)

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/Phybdqb0SV0/iom-california-stem-cell-directors.html

Related Post

This entry was posted on January 27, 2013 at 8:06 am and is filed under Stem Cell Therapy. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |

Comments are closed.

2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick